4SCAR19U T Cells Targeting B Cell Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05995015 |
Recruitment Status :
Recruiting
First Posted : August 16, 2023
Last Update Posted : October 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
B Cell Malignancies | Biological: Universal CD19-specific CAR gene-engineered T cells | Phase 1 |
Chimeric antigen receptor (CAR) T cell therapy has proven effective in treating B cell malignancies. However, the application itself is still limited by the high cost and long preparation time which often do not meet the urgent need of patients. In addition, some patients may suffer from long-term immunosuppression caused by tumor microenvironment or after radiotherapy and chemotherapy, resulting in exhaustion, aging and functional defects of the autologous T cells, which will eventually affect the quality of the CAR-T cells and affect the clinical efficacy.
The 4SCAR19U T cells are genetically engineered and manufactured in bulk amount that can be supplied off-the-shelf without being custom made from individual patients. The immediate availability of the CAR-T cells makes clinical treatment convenient and timely for rapid progressing disease or for the highly immune suppressed patients. This application can be time- and cost-effective. This novel approach may also overcome problems of functionally defective autologous T cells. The purpose of this clinical trial is to assess the feasibility, safety and efficacy of the 4SCAR19U T cell product in hematological malignancies. Another goal of the study is to learn more about the function of this novel product and its persistence in the patients
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Universal 4SCAR19U T Cell Therapy for the Treatment of Relapsed and Refractory B Cell Malignancies |
Estimated Study Start Date : | October 31, 2023 |
Estimated Primary Completion Date : | September 30, 2026 |
Estimated Study Completion Date : | December 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Universal 4SCAR19U cells to treat CD19-positive hematological malignancies |
Biological: Universal CD19-specific CAR gene-engineered T cells
Infusion of 4SCAR19U cells |
- Safety of 4SCAR19U CAR-T cells infusion [ Time Frame: 24 weeks ]Safety of 4SCAR19U T cells in patients with relapsed and refractory B-ALL, BCL using CTCAE 4 standard to evaluate the level of adverse events
- Anti-tumor activity of 4SCAR19U cells after infusion [ Time Frame: 1 year ]Objective responses (complete response (CR) + partial response (PR)) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age older than 6 months.
- Primary B cell surface expression of CD19.
- The KPS score over 80 points, and survival time is more than 1 month.
- Greater than Hgb 80 g/L.
- No contraindications to blood cell collection.
Exclusion Criteria:
- Accompanied with other active diseases, and difficult to assess response after treatment.
- Bacterial, fungal, or viral infection, unable to control.
- Living with HIV.
- Active HBV or HCV infection.
- Pregnant and nursing mothers.
- under systemic steroid treatment within a week of the treatment.
- Prior failed CAR-T treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05995015
Contact: Lung-Ji Chang, Ph.D | +86-0755 8672-5195 | c@szgimi.org |
China, Guangdong | |
Shenzhen Geno-Immune Medical Institute | Recruiting |
Shenzhen, Guangdong, China, 518000 | |
Contact: Lung-Ji Chang, Ph.D +86-0755 8672-5195 c@szgimi.org |
Responsible Party: | Shenzhen Geno-Immune Medical Institute |
ClinicalTrials.gov Identifier: | NCT05995015 |
Other Study ID Numbers: |
GIMI-IRB-23001 |
First Posted: | August 16, 2023 Key Record Dates |
Last Update Posted: | October 12, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Universal CAR-T CD19 B-ALL PMBCL CNS-BCL BCL |
Neoplasms |